Montreal,, September 12, 2025 / Prnewswire / – A concerted effort of the World Hemophilia Federation (WFH) and its partners has led the World Health Organization (WHO) to update its essential list of drugs (EML) and the list of essential drugs for children (EMLC) to better align EMLS disease on international clinical guidelines for the management of hemophilia and the disease of Von Willebrand (VWDD). These revisions will have a positive impact on the lives of people with bleeding disorders (PWBD) everywhere.
WHO EML has an essential role in the guidance of national governments on the selection and financing of essential drugs for a range of conditions, including hemophilia. These revisions mean that decision -makers will use up -to -date recommendations when making key decisions that will have an impact on the treatment of hemophilia.
“WHO Updates mean that thousands of PWBDs now have a bigger hope for a better future. WFH is proud to have directed a united global effort to make this stage possible. Together, we are shaping a future where our vision of treatment for all can become a reality.”
– Enter Garrido, President, WFH
The request for update of the EML WHO has been built on key revisions necessary to improve lists for the processing of hemophilia and VWD. Today, prophylaxis is the internationally recognized standard of care for people with hemophilia. A range of virally safe and effective therapies is available for people with hemophilia and VWD. Conversely, cryoprepility (whether reduced by pathogens, PR-Cryo or not) cannot be used for prophylaxis. In addition, cryoprepility presents a significant risk of transmission of blood infections.
The revisions brought in the 24th EML and 10th EMLC recently published will contribute to increasing fair access to safer and more effective therapies for PWBDs worldwide. You will find below the critical modifications made to the EML and the EMLC, compared to the drugs indicated for the treatment of hemophilia and VWD.
New drugs added to EML and EMLC
- The bi-specific monoclonal antibody, Emizumab, was included on the basic list
- FVIII Recombinant and coagulation factor concentrates (CFC) were included on the basic list
Revisions made to existing drugs listed on EML and EMLC
- FVIII derived from plasma and the fixing CFCs were transferred from the complement to the basic list
- Desmopressin was transferred from the complement to the basic list
Drugs or formulations deleted on EML and EMLC
- Cryoprepility reduced by pathogens and not reduced by pathogens have been eliminated as indications for the treatment of hemophilia and VWD
- The factor of factor IX (also known as a prothrombin complex concentrate (CCC)) has been deleted as a therapeutic alternative to fix the CFCs
“The WHO’s decision to update the essential drug lists marks a major advance to guarantee access to modern and effective treatments for people with bleeding disorders worldwide. This step was only possible thanks to the strong support and collaboration of the best clinical standards, which makes EML a better advocacy tool to domestic patients and families that are not consulted.”
—Glenn Pierce, MD, PHD, vice-president, medical, WFH
This important step for our community was carried out thanks to a joint effort led by WFH, stressing the commitment to large range between institutions, experts and organizations to update the EML.
The process included WFH entering a direct dialogue in two years with the WHO headquarters and consulting the EML secretariat throughout the request process. WFH was also an active participant in the meeting of the 25th WHO Expert Committee on the selection and use of essential drugs, and made a declaration in favor of updating directives during the public session on May 5, 2025.
The WFH also summarized its concerns concerning the obsolete recommendations of the “risk of damage for people with hemophilia in the list of essential drugs of 2023” published in THe launched hematology In September 2024.
WFH wishes to recognize and express its gratitude to its national organizations (NMOS), expert clinicians, hemophilia treatment centers (HTC) and scientific and defense associations from around the world who have supported this business. A joint support letter concerning the director general of the WHO was approved by 115 NMOS WFH, while another was signed by more than 120 expert clinicians representing all regions of the world. Additional individual letters of support come from the main medical associations and patients, including the European Association for Hemophilia and Allied Disorders (EAHAD), European Hemophilia Consortium (EHC), International Thrombose and Hemostasis Society (ISTH), the Association for Hemophilia and Allied disorders – Asia-Pacific (Sunday-AP), Latin American cooperative group of hemostasis and thrombosis (Claht), the association for the Advancement of Blood and Biotherapies (AABB), the Association Indian Association for Haemophilia and Allied Disorders (IAHAD), International Patient Organization for Primary Immunodfications (IPOPI), Rare Diseases International (RDI), The Plasma Protein Therapeutics Association (PPTA), The International Plasma and Fracation Association (IPFA), Ceruse, Corpation and Notor Plasma and Fraction Association (IPFA), Ceruse, Corpation and Notor Organizations.
This wealth of support from our NMOS, experts, experts, partners and scientific associations and collaborating patients is a real testimony to how our global community of bleeding disorders can meet for a common cause and at the service of our shared vision of treatment for all.
The three WFH submissions for update in 2025 EML and EMLC, respective support letters and the WFH declaration made at the meeting of the 25th WHO Expert Committee on the selection and use of essential drugs may be seen here.
To see the WFH publication on “risk of damage for people with hemophilia in the list of essential drugs of 2023” published in THe launched hematology, please Click here.
To see recently published 24th List of essential drugs and the 10thth List of essential drugs for the children of the World Health Organization (WHO), please Click here.
On hemophilia and other bleeding disorders
In people with bleeding disorders, the blood clotting process does not work properly, with the result that they can bleed longer than normal, and some people may experience spontaneous bleeding in joints, muscles, internal organs or other parts of their body, which can cause serious health complications and even be fatal if it is not treated.
On the World Hemophilia Federation
THE World Hemophilia Federation (WFH) is a non -profit organization dedicated to the improvement and maintenance of care for people with hereditary bleeding disorders in the world. At WFH, national organizations (ONM) and health professionals (HCP) work together to provide care for people with hereditary bleeding problems in the world. We associate ourselves with the governments and treatment centers of hemophilia to improve knowledge through training and to provide tools they need to identify, support and treat people living with bleeding disorders in their communities, while promoting world advocacy and collaboration to achieve our common goals. WFH is based on fundamental values and the following organizational principles: patients first, collaboration, integrity, respect, solidarity and excellence.
Our vision of treatment for everyone is for a world where all people with hereditary bleeding disorders have access to care, regardless of their type of bleeding, sex or where they live. Our mission is to improve and maintain care for people with bleeding problems inherited from the whole world.
To find out more about WFH, please visit www.wfh.org.
Media contact:
Neha Suchak
Director, Marketing and Communications
nsuchak@wfh.org
+1 514-875-7944, # 2857
www.wfh.org
World Hemophilia Federation Source
